There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Qiushan Tao |
| Institution: | Boston University |
| Department: | Pharmacology & Experimental Therapeutics |
| Country: | |
| Proposed Analysis: | Biomarkders are critical to the development of disease-modifying or preventative therapies. We aimed to study the plasma biomarkers, such as phospholipids, Aβ40, Aβ42 and Tau, for the diagnosis of Alzheimer’s disease (AD) and/or Mild Cognitive Impairment (MCI). We had successfully built a predictive model based on a a set of selective phosphatidylcholines (PC), Aβ40, Aβ42 and Tau based on a small sample clinical trail in our lab, we need a larger sample as an outside cross-validation data source, and we believe that ADNI is a good open data source for those biomarkers related to AD and/or MCI. We feel strongly that our predictive model are the best candidate for the diagnosis of Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI) to date. |
| Additional Investigators | |
| Investigator's Name: | Mengqi Tao |
| Proposed Analysis: | This study aims to develop an advanced machine learning model using the extensive ADNI dataset to identify new biomarkers for Alzheimer's disease (AD) dementia. Through rigorous data preprocessing and exploration of state-of-the-art algorithms, we seek to uncover biomarkers that enhance early detection and deepen our understanding of AD progression. Labeled data from ADNI will be used to train the model, with cross-validation employed to optimize performance. By achieving our objective, this research has the potential to advance early detection, improve diagnostics, and enable targeted interventions and personalized treatment strategies for AD. Ultimately, this study holds significant promise for making a meaningful impact in the field of AD research, enhancing patient care, and improving outcomes. |
